CN106309401A - Bathing effervescent tablets for preventing and treating skin diseases - Google Patents

Bathing effervescent tablets for preventing and treating skin diseases Download PDF

Info

Publication number
CN106309401A
CN106309401A CN201610895203.0A CN201610895203A CN106309401A CN 106309401 A CN106309401 A CN 106309401A CN 201610895203 A CN201610895203 A CN 201610895203A CN 106309401 A CN106309401 A CN 106309401A
Authority
CN
China
Prior art keywords
acid
effervescent tablets
source
mix homogeneously
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610895203.0A
Other languages
Chinese (zh)
Inventor
贺晓军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Huidoctor Biotechnology Co Ltd
Original Assignee
Hangzhou Huidoctor Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Huidoctor Biotechnology Co Ltd filed Critical Hangzhou Huidoctor Biotechnology Co Ltd
Priority to CN201610895203.0A priority Critical patent/CN106309401A/en
Publication of CN106309401A publication Critical patent/CN106309401A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Cosmetics (AREA)

Abstract

The invention discloses bathing effervescent tablets. The bathing effervescent tablets contain the following components in percentage by weight: 0.5-2.0% of hyaluronic acid, 8.0-15% of dried composition powder, 0.1-0.2% of dipotassium glycyrrhizinate, 10-30% of an acid source, 10-30% of an alkali source and 30-70% of excipients. The effervescent tablets disclosed by the invention have good antibacterial effects on Escherichia coli, staphylococcus aureus, pseudomonas aeruginosa and candida albicans and can achieve the aims of preventing and treating skin diseases.

Description

A kind of bath effervescent tablets for preventing and treat dermatosis
Technical field
The present invention relates to effervescent tablet technology, particularly to bath effervescent tablets.
Background technology
In recent years, along with the continuous change of human life style, being continually changing and age, psychology pressure of living environment The impact of factor, the sickness rate of China's dermatosis such as power, environmental pollution, seasonal variations present continuous ascendant trend；At present, though There is a treatment for dermatosis of a lot of for oral administration and external method, but to there is the cause of disease complicated due to dermatosis, treats difficulty more Greatly, the feature such as treatment time length, weak effect, easy recurrence, therefore, in terms for the treatment of, also lack effective method.
Therapeutic Method used by clinic mostly is hormones for oral administration, calm class chemical drugs at present, the best secondary work of therapeutic effect With the biggest, the treatment for dermatosis brings bigger difficulty, therefore, for dermatosis, and particularly chronic skin disease, Also in the symptomatic treatment stage on clinical treatment, exploitation is safe and effective, and therapeutic effect significantly a new generation's treating skin disease Method is very important；Bath effervescent tablets containing multiple efficacies composition can not only solve common bath product soap, shower Decontamination degree is not enough in cleaning bathing experience for liquid, shower cream etc., it is slow to bubble, foam number is few, foam duration is short and after washing The greasy shortcoming such as rough of health, moreover it is possible to utilize the antiinflammatory bacteriostasis efficacy of Multiple components rationally to prevent and treat dermatosis, make People is maintaining skin while cleaning skin.
Summary of the invention
According to an aspect of the invention, it is provided bath effervescent tablets, including the component hyaluronic acid of following part by weight 0.5-2.0%, compositions dry powder 8.0-15%, glycyrrhizic acid dipotassium 0.1-0.2%, acid source 10-30%, alkali source 10-30%, figuration Agent 30-70%.
In certain embodiments, bath effervescent tablets includes the component hyaluronic acid 1.0-1.5% of following part by weight, combination Thing dry powder 10.0-12%, glycyrrhizic acid dipotassium 0.12-0.15%, acid source 15-20%, alkali source 15-20%, excipient 40-60%.
In certain embodiments, bath effervescent tablets includes the component hyaluronic acid 1.0% of following part by weight, and compositions is done Powder 10.0%, glycyrrhizic acid dipotassium 0.15%, acid source 20%, alkali source 18.85%, excipient 50%.
Wherein, hyaluronic acid has antiinflammatory bacteriostatic activity and moisture-keeping function；Glycyrrhizic acid dipotassium have antibacterial, antiinflammatory, removing toxic substances, The multiple efficacies such as antiallergic, deodorization.
In certain embodiments, compositions dry powder includes Flos Matricariae chamomillae, Princepia utilis and Flos Chrysanthemi Indici.Flos Matricariae chamomillae has suppression and kills Bacterium, antiinflammatory, releive etc. acts on；The irritation test of Princepia utilis multiple dosing shows, has no stimulation human body skin, can Effectively to alleviate the inflammation caused by the pro-inflammatory cytokines such as histamine and anaphylaxis, In Vitro Bacteriostasis test shows have significantly Antiinflammatory, fungistatic effect；Flos Chrysanthemi Indici has the effect that sterilization goes to swell；
In certain embodiments, the preparation method of compositions dry powder is: take compositions Flos Matricariae chamomillae 300 grams, Princepia utilis 600 Gram, Flos Chrysanthemi Indici 100 grams, mixed powder is broken into coarse powder, adds 10 times amount water, decocting in water 2 hours, filtration treatment, and filtering residue adds 8 times amount water, water Boil 1 hour, filtration treatment；Filtering residue adds the water of 8 times amount, decocting in water 1 hour, filtration treatment again, and filtrate merges, reduces pressure dense at 50 DEG C Being reduced to the clear paste that relative density is 1.0g/ml, add ethanol and make alcohol content reach 60%, stand 24 hours, filter, filtrate decompression reclaims Ethanol is also concentrated into without alcohol taste, standby；Take above-mentioned composition filtrate spray-dried after become dry powder, seal and preserve, standby.
In certain embodiments, bath effervescent tablets, acid source is in citric acid, tartaric acid, fumaric acid, adipic acid, malic acid One or more.
In certain embodiments, bath effervescent tablets, alkali source is sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, carbonic acid One or more in calcium.
In certain embodiments, the preferred sodium chloride of filler, starch, sorbitol, Herba Menthae, dextrin, lactose, milk powder, sucrose, One or more in glucose, mannose, maltose.
In certain embodiments, mint smell fragrance, there is effect of anthelmintic, can produce refrigerant for skin or mucosa Sense, can effectively palliate a disease cause do not accommodate pain.
In certain embodiments, foaming agent preferred amino acid solid foaming agents.
In certain embodiments, binding agent: preferred starch slurry, ethanol water, olefin(e) acid resin aqueous solution, ethanol, syrup In one or more.
In certain embodiments, lubricant: preferably Polyethylene Glycol, sodium lauryl sulphate, leucine, sodium benzoate, mountain One or more in potassium sorbate, boric acid, sodium acetate, wherein Polyethylene Glycol is optimal, also may be used while having lubrication As thickening agent and alkali source covering.
In certain embodiments, Polyethylene Glycol: described Polyethylene Glycol is Macrogol 4000 or polyethylene glycol 6000.
In certain embodiments, bath effervescent tablets, excipient includes filler, foaming agent, binding agent, lubricant, anticorrosion One or more in agent, essence, pigment.
In certain embodiments, the preparation method of bath effervescent tablets, comprise the steps:
Step S1, being dried 2 hours under the conditions of 80-100 DEG C by acid source, alkali source is dried 2 little under the conditions of 100-120 DEG C Time, pulverized 100 mesh sieves, mix homogeneously respectively, and sealed and be cooled to 40 DEG C；
Step S2, by hyaluronic acid, compositions dry powder, glycyrrhizic acid dipotassium add step a mix homogeneously, grinding；
Step S3, excipient is added above-mentioned material mix homogeneously, grinding, seal and be put in 40-80 DEG C of oven drying 10- 30min；
Step S4, will spray ethanol solution Polyethylene Glycol add above-mentioned material, mix homogeneously, cross 140 mesh sieves, put into pressure Sheet machine carries out tabletting, obtains effervescent tablet.
Proving through bacteriostatic test, bath effervescent tablets of the present invention is to Clinical isolation escherichia coli, Staphylococcus aureus Bacterium, bacillus pyocyaneus, Candida albicans all have stronger bacteriostasis, it is possible to prevent and treat dermatosis.
Detailed description of the invention
The preparation of embodiment 1 effervescent tablet
Formula (part by weight): hyaluronic acid, 1.0%, compositions dry powder, 10.0%, glycyrrhizic acid dipotassium 0.1%, Fructus Citri Limoniae Acid 15%, sodium bicarbonate 20%, sodium chloride 45.0%, Herba Menthae 3.0%, Macrogol 4000 2.0%, aminoacid foaming agent 2.0%, sodium formate 0.5%, ethanol 0.9%, essence 0.5%.
Preparation method
A, being dried 2 hours under the conditions of 80 DEG C by citric acid, sodium bicarbonate is dried 2 hours under the conditions of 120 DEG C, respectively powder Broken mistake 100 mesh sieve, mix homogeneously, seal and be cooled to 40 DEG C；
B, by hyaluronic acid, compositions dry powder, glycyrrhizic acid dipotassium add step a mix homogeneously, grinding；
C, by sodium chloride, Herba Menthae, aminoacid foaming agent, sodium benzoate, essence add above-mentioned material mix homogeneously, grinding, Sealing is put in 50 DEG C of oven drying 20min；
D, will spray ethanol solution Macrogol 4000 add above-mentioned material, mix homogeneously, cross 140 mesh sieves, put into pressure Sheet machine carries out tabletting, obtains effervescent tablet.
The preparation of embodiment 2 effervescent tablet
Formula (part by weight): hyaluronic acid 2.0%, compositions dry powder 15%, glycyrrhizic acid dipotassium 0.2%, citric acid 30%
Sodium bicarbonate 30%, sodium chloride 2.0%, lactose 2.0%, Herba Menthae 5.0%, Macrogol 4000 2.0%, aminoacid Foaming agent 10%, sodium benzoate 0.5%, ethanol 0.8%, essence 0.5%.
Preparation method:
A, being dried 2 hours under the conditions of 80 DEG C by citric acid, sodium bicarbonate is dried 2 hours under the conditions of 120 DEG C, respectively powder Broken mistake 100 mesh sieve, mix homogeneously, seal and be cooled to 40 DEG C；
B, by hyaluronic acid, compositions dry powder, glycyrrhizic acid dipotassium add step a mix homogeneously, grinding；
C, by sodium chloride, lactose, Herba Menthae, aminoacid foaming agent, sodium benzoate, essence add above-mentioned material mix homogeneously, Grind, seal and be put in 60 DEG C of oven drying 25min；
D, will spray ethanol solution Macrogol 4000 add above-mentioned material, mix homogeneously, cross 140 mesh sieves, put into pressure Sheet machine carries out tabletting, obtains effervescent tablet.
The preparation of embodiment 3 effervescent tablet
Formula (part by weight): hyaluronic acid 1.0%, compositions dry powder 12%, glycyrrhizic acid dipotassium 0.1%, tartaric acid 20%, sodium bicarbonate 20%, sodium carbonate 5.0%, sodium chloride 20%, sorbitol 8.0%, Herba Menthae 5.0%, Macrogol 4000 2.0%, aminoacid foaming agent 5.0%, sodium benzoate 0.5%, ethanol 0.9%, essence 0.5%.
Preparation method:
A, being dried 2 hours under the conditions of 100 DEG C by citric acid, sodium bicarbonate and sodium carbonate are dried 2 little under the conditions of 100 DEG C Time, pulverized 100 mesh sieves, mix homogeneously respectively, and sealed and be cooled to 40 DEG C；
B, by hyaluronic acid, compositions dry powder, glycyrrhizic acid dipotassium add step a mix homogeneously, grinding；
C, sodium chloride, sorbitol, Herba Menthae, aminoacid foaming agent, sodium benzoate, essence are added the mixing of above-mentioned material all Even, grinding, seals and is put in 60 DEG C of oven drying 30min；
D, will spray ethanol solution Macrogol 4000 add above-mentioned material, mix homogeneously, cross 140 mesh sieves, put into pressure Sheet machine carries out tabletting, obtains effervescent tablet.
Embodiment 4:
Formula (part by weight): hyaluronic acid 0.5%, compositions dry powder 8.0%, glycyrrhizic acid dipotassium 0.1%, citric acid 10%, sodium bicarbonate 15%, sodium chloride 20%, lactose 14%, milk powder 15%, Herba Menthae 5.0%, Macrogol 4000 2.0%, ammonia Base acid foaming agent 8.5%, sodium benzoate 0.5%, ethanol 0.9%, essence 0.5%.
Preparation method:
A, being dried 2 hours under the conditions of 80 DEG C by citric acid, sodium bicarbonate is dried 2 hours under the conditions of 120 DEG C, respectively powder Broken mistake 100 mesh sieve, mix homogeneously, seal and be cooled to 40 DEG C；
B, by hyaluronic acid, compositions dry powder, glycyrrhizic acid dipotassium add step a mix homogeneously, grinding；
C, by sodium chloride, lactose, milk powder, Herba Menthae, aminoacid foaming agent, sodium benzoate, essence add above-mentioned material mixing Uniformly, grind, seal and be put in 50 DEG C of oven drying 30min；
D, will spray ethanol solution Macrogol 4000 add above-mentioned material, mix homogeneously, cross 140 mesh sieves, put into pressure Sheet machine carries out tabletting, obtains effervescent tablet.
Embodiment 5
Formula (part by weight): hyaluronic acid 1.0%, compositions dry powder 10.0%, glycyrrhizic acid dipotassium 0.15%, citric acid 20%, sodium bicarbonate 18.85%, sodium chloride 10%, lactose 13%, milk powder 10%, Herba Menthae 5.0%, Polyethylene Glycol 40002.0%, aminoacid foaming agent 8%, sodium benzoate 0.5%, ethanol 1.0%, essence 0.5%.
Preparation method:
A, being dried 2 hours under the conditions of 80 DEG C by citric acid, sodium bicarbonate is dried 2 hours under the conditions of 120 DEG C, respectively powder Broken mistake 100 mesh sieve, mix homogeneously, seal and be cooled to 40 DEG C；
B, by hyaluronic acid, compositions dry powder, glycyrrhizic acid dipotassium add step a mix homogeneously, grinding；
C, by sodium chloride, lactose, milk powder, Herba Menthae, aminoacid foaming agent, sodium benzoate, essence add above-mentioned material mixing Uniformly, grind, seal and be put in 50 DEG C of oven drying 30min；
D, will spray ethanol solution Macrogol 4000 add above-mentioned material, mix homogeneously, cross 140 mesh sieves, put into pressure Sheet machine carries out tabletting, obtains effervescent tablet.
Test a bacteriostatic experiment
Take Clinical isolation escherichia coli, staphylococcus aureus, bacillus pyocyaneus, Candida albicans a little, connect respectively Plant in broth bouillon, at 37 DEG C, cultivate 18h.(adding the calf serum of 20% in bacillus pyocyaneus broth bouillon) takes Each bacterial strain nutrient broth culture that 18h cultivates, is made into bacteria suspension for testing.Take sterilizing test tubes 11, the 1st addition Nutrient broth fluid medium 9ml, 2-10 prop up addition 5ml, and the 11st adds 10ml, take the present embodiment bath effervescent tablets and dissolve Liquid 1ml adds the 1st test tube, takes 5ml and add the 2nd after mix homogeneously, is diluted to the 10th successively, and the 11st is not added with sample and does For comparison.Often pipe adds escherichia coli suspension 0.1ml, cultivates 24h, take out and observe bacterial growth situation at a temperature of 37 DEG C.Gold Staphylococcus aureus, bacillus pyocyaneus, Candida albicans are with above-mentioned laboratory observation growing state.As test tube becomes cloudy, i.e. represent thin Bacteria growing, sample is without bacteriostasis；As test tube is limpid, represent that bacterial growth is suppressed.Experimental result is as shown in table 1, this Clinical isolation escherichia coli, staphylococcus aureus, bacillus pyocyaneus, Candida albicans are all had stronger by bright bath effervescent tablets Bacteriostasis.
Each test tube bacterial growth situation in table 1 embodiment one
Note: " " represents that test tube becomes cloudy；"+", represents that test tube is limpid.
By above-mentioned limpid broth tubes (1-4) and matched group transferred species broth agar plates, observe 24h, without bacterial growth Cmin be bacteriocidal concentration, be designated as C, unit is mg/mL, and result is as shown in table 2, and the bath effervescent tablets of the present invention is described Clinical isolation escherichia coli, staphylococcus aureus, bacillus pyocyaneus, Candida albicans all there is stronger bactericidal action.
Table 2 embodiment one sterilization conditions
Note: " " indicates without bactericidal properties.
Test two clinical trials
Now use the biologically active human of the method detection bath effervescent tablets of human experimentation, i.e. antiinflammatory bacteriostatic activity, research Bath effervescent tablets is with prevention and treatment dermatosis.
The all experimenters of this experiment are dermatosis patient in various degree, and experimental group 1 uses compositions dry powder 10.0%+ Glycyrrhizic acid dipotassium 0.1%+ hyaluronic acid 1.0% bath effervescent tablets is slept front with 1 time every night；Experimental group 2 uses compositions dry powder 10.0%+ hyaluronic acid 1.0% bath effervescent tablets is slept front with 1 time every night；Experimental group 3 uses glycyrrhizic acid dipotassium 0.1%+ hyalomitome Acid 1.0% bath effervescent tablets is slept front with 1 time every night；It is front with 1 time that positive control uses 1.0% hyaluronic acid effervescent sheet to sleep every night； It is front with 1 time that negative control uses common bath oil to sleep every night；After comparison five groups is treated 14 days, symptom improves situation.
The symptom therapeutic evaluatioies such as dermal sensation discomfort, allergy, inflammation, abnormal flavour, spot:
Effective: symptom significantly improves or disappears, patient satisfaction；It is effective: symptom has improvement or alleviates, and patient still has discomfort, Require continual cure；Invalid: symptom is without substantially alleviating, and patient is unsatisfied with.
Statistical method: use SPSS12.0 statistics software to carry out statistical procedures, compare between metering and enumeration data group Relatively use t inspection and x2Inspection, with p < 0.05 for statistically significant difference.
Result is as follows:
As shown in table 3, the 15th day symptom improvement situation: effective 10 examples of experimental group 1, total effective rate 100%；Experimental group 2 shows Imitating 1 example, effective 9 examples, total effective rate 100%, obvious effective rate compares P < 0.01 with experimental group 1；Effective 0 example of experimental group 3, effective 7 examples, Invalid 3 examples, total effective rate 70%, obvious effective rate compares P < 0.01 with experimental group 1；Effective 2 examples of positive control, effective 8 examples, the most effectively Rate 100%, obvious effective rate compares P < 0.01 with experimental group 1.
The 15th day each group patients symptomatic of table 3 improves situation and is compared as follows:
Group Sample number Effective Effectively Invalid Total effective rate (%)
Experimental group 1 10 10 0 0 100
Experimental group 2 10 1 9 0 100
Experimental group 3 10 0 7 3 70
Positive control 10 2 8 0 100
Negative control 10 0 0 10 0
Conclusion:
Experimental group 1 (compositions dry powder 10.0%+ glycyrrhizic acid dipotassium 0.1%+ hyaluronic acid 1.0%) is substantially than experimental group 2 (compositions dry powder 10.0%+ hyaluronic acid 1.0%), experimental group 3 (glycyrrhizic acid dipotassium 0.1%+ hyaluronic acid 1.0%), the positive Comparison is effectively.Present invention human experimentation shows the shower that (1) compositions dry powder, glycyrrhizic acid dipotassium and hyaluronic acid three compound Effervescent tablet is evident in efficacy to prevention and treatment dermatosis；(2) compositions dry powder and glycyrrhizic acid dipotassium to hyaluronic acid prevention and The curative effect for the treatment of dermatosis has obvious synergism.

Claims (8)

1. bath effervescent tablets, it is characterised in that include the component hyaluronic acid 0.5-2.0% of following part by weight, compositions is done Powder 8.0-15%, glycyrrhizic acid dipotassium 0.1-0.2%, acid source 10-30%, alkali source 10-30%, excipient 30-70%.
Bath effervescent tablets the most according to claim 1, it is characterised in that include the component hyaluronic acid of following part by weight 1.0-1.5%, compositions dry powder 10.0-12%, glycyrrhizic acid dipotassium 0.12-0.15%, acid source 15-20%, alkali source 15-20%, Excipient 40-60%.
Bath effervescent tablets the most according to claim 2, it is characterised in that include the component hyaluronic acid of following part by weight 1.0%, compositions dry powder 10.0%, glycyrrhizic acid dipotassium 0.15%, acid source 20%, alkali source 18.85%, excipient 50%.
Bath effervescent tablets the most according to claim 1, it is characterised in that described compositions dry powder includes Flos Matricariae chamomillae, blue or green thorn Fruit and Flos Chrysanthemi Indici.
Bath effervescent tablets the most according to claim 1, it is characterised in that described acid source is citric acid, tartaric acid, rich horse One or more in acid, adipic acid, malic acid.
Bath effervescent tablets the most according to claim 1, it is characterised in that described alkali source is sodium carbonate, sodium bicarbonate, carbonic acid One or more in potassium, potassium bicarbonate, calcium carbonate.
Bath effervescent tablets the most according to claim 1, it is characterised in that described excipient includes filler, foaming agent, glues One or more in mixture, lubricant, preservative, essence, pigment.
8. the preparation method of bath effervescent tablets as claimed in claim 1, it is characterised in that comprise the steps:
Step S1, by acid source under the conditions of 80-100 DEG C be dried 2 hours, alkali source under the conditions of 100-120 DEG C be dried 2 hours, point Do not pulverized 100 mesh sieves, mix homogeneously, and sealed and be cooled to 40 DEG C；
Step S2, by hyaluronic acid, compositions dry powder, glycyrrhizic acid dipotassium add step a mix homogeneously, grinding；
Step S3, excipient is added above-mentioned material mix homogeneously, grinding, seal and be put in 40-80 DEG C of oven drying 10-30min；
Step S4, will spray ethanol solution Polyethylene Glycol add above-mentioned material, mix homogeneously, cross 140 mesh sieves, put into tablet machine Carry out tabletting, obtain effervescent tablet.
CN201610895203.0A 2016-10-14 2016-10-14 Bathing effervescent tablets for preventing and treating skin diseases Pending CN106309401A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610895203.0A CN106309401A (en) 2016-10-14 2016-10-14 Bathing effervescent tablets for preventing and treating skin diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610895203.0A CN106309401A (en) 2016-10-14 2016-10-14 Bathing effervescent tablets for preventing and treating skin diseases

Publications (1)

Publication Number Publication Date
CN106309401A true CN106309401A (en) 2017-01-11

Family

ID=57817597

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610895203.0A Pending CN106309401A (en) 2016-10-14 2016-10-14 Bathing effervescent tablets for preventing and treating skin diseases

Country Status (1)

Country Link
CN (1) CN106309401A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108186372A (en) * 2017-12-29 2018-06-22 青岛百瑞吉生物工程有限公司 A kind of whitening and skin-protecting bathing effervescent tablet and preparation method thereof
CN108542804A (en) * 2018-03-21 2018-09-18 厦门舒菲娅化妆品有限公司 A kind of infant of the cleansing containing amino acid mildly baths effervescent tablet and preparation method thereof
CN109528509A (en) * 2018-11-06 2019-03-29 广东轻工职业技术学院 A kind of moisture-proof effervesce bath balls and preparation method thereof
CN110559208A (en) * 2019-10-15 2019-12-13 华熙生物科技股份有限公司 Bathing effervescent tablet containing hyaluronic acid
CN111150664A (en) * 2020-01-09 2020-05-15 东莞市星泽日用品有限公司 Moisture-proof particle bath salt ball and preparation method thereof
US11839208B2 (en) 2016-06-02 2023-12-12 Pharmotech Sa Cannabidiol compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105125702A (en) * 2015-08-19 2015-12-09 哈尔滨灵草舒生物科技有限公司 White poplar bark wind-dispelling bath effervescent tablet and preparing method of white poplar bark wind-dispelling bath effervescent tablet
CN105769605A (en) * 2016-04-25 2016-07-20 武文博 Cosmetic containing human active hyaluronic acid or human active hyaluronate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105125702A (en) * 2015-08-19 2015-12-09 哈尔滨灵草舒生物科技有限公司 White poplar bark wind-dispelling bath effervescent tablet and preparing method of white poplar bark wind-dispelling bath effervescent tablet
CN105769605A (en) * 2016-04-25 2016-07-20 武文博 Cosmetic containing human active hyaluronic acid or human active hyaluronate

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11839208B2 (en) 2016-06-02 2023-12-12 Pharmotech Sa Cannabidiol compositions and uses thereof
CN108186372A (en) * 2017-12-29 2018-06-22 青岛百瑞吉生物工程有限公司 A kind of whitening and skin-protecting bathing effervescent tablet and preparation method thereof
CN108542804A (en) * 2018-03-21 2018-09-18 厦门舒菲娅化妆品有限公司 A kind of infant of the cleansing containing amino acid mildly baths effervescent tablet and preparation method thereof
CN109528509A (en) * 2018-11-06 2019-03-29 广东轻工职业技术学院 A kind of moisture-proof effervesce bath balls and preparation method thereof
CN110559208A (en) * 2019-10-15 2019-12-13 华熙生物科技股份有限公司 Bathing effervescent tablet containing hyaluronic acid
CN111150664A (en) * 2020-01-09 2020-05-15 东莞市星泽日用品有限公司 Moisture-proof particle bath salt ball and preparation method thereof

Similar Documents

Publication Publication Date Title
CN106309401A (en) Bathing effervescent tablets for preventing and treating skin diseases
CN105189732B (en) Prevent and/or treat the method with the relevant infection of pathogenic bacteria, field planting or disease
CN101791319B (en) Female pudendum nursing product
CN102028705B (en) Gynecologic article containing biological antifungal components
CN106581148A (en) Nasal irrigation care solution
CN101361535B (en) Compound pollen cream and preparation method thereof
CN108042578A (en) A kind of health care vaginal jellies containing compound probiotic ingredient
CN111449973A (en) Foaming agent for restoring microecological balance of female vagina and preparation method thereof
TW200826953A (en) Agonist for healing living organisms
KR20190014774A (en) Atopic dermatitis remedy and method for producing the same
CN101797269B (en) Physiological balance liquid for adjusting microecology in vaginas of women
CN106726896A (en) A kind of beautifying health composition with anti-inflammatory bacteriostasis efficacy and preparation method thereof
CN111297961A (en) Dong medicine for promoting wound healing
CN110559233A (en) traditional Chinese medicine toothpaste for resisting oral helicobacter pylori and preparation method thereof
CN1751577A (en) Composite sterilizing agent contg. silver and zinc, prepn. method and application thereof
CN1672689A (en) Nano silver antiseptic gel for treating women&#39;s genital tract infection and its prepn and application
CN107281001A (en) A kind of activity conditioning spraying containing hyaluronic acid and preparation method thereof
CN106668331A (en) Composition having functions of diminishing inflammation, inhibiting bacteria and promoting wound healing and preparation method thereof
CN114306526B (en) Compound broadleaf holly leaf traditional Chinese medicine extract and application thereof in preparing shower gel or hand sanitizer
CN113616774B (en) Antibacterial composition containing plant stem cells, maintenance antibacterial liquid and preparation method thereof
CN109010353A (en) A kind of biological polyoses material compositions for treating chemicotherapy patient&#39;s oral mucosa ulcer
CN108434509A (en) Chinese medicine antibacterial paper diaper detachably containing graphene oxide-copper silver nanoparticle compound
CN108578502A (en) A kind of Chinese medicine composition and preparation method thereof of nourishing the stomach protect liver
CN104000767B (en) A kind of Feminine care solution and preparation method thereof
CN107174535A (en) A kind of hyaluronic acid compositions and application with the transdermal reparation effect of anti-inflammatory

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170111

RJ01 Rejection of invention patent application after publication